Newsfeeds - Spark Newswire

2 minute read

Inhibrx Says Initiates Potential Registration-Enabling Phase 2 Study Of INBRX-109 In Conventional Chondrosarcoma Patients; Says Updates Data For Ongoing Phase 1 Study; Announces Amended Loan Agreement With Oxford

Today, 8:04 PM

Inhibrx, Inc. (NASDAQ:INBX), a biotechnology company with four clinical programs in development, announced initiation of a potential registration-enabling Phase 2 study of INBRX-109 in conventional

INBX

2 minute read

Movers

12 Health Care Stocks Moving In Thursday’s After-Market Session

By Benzinga Insights

Today, 8:04 PM

Gainers

AXLA

5 minute read

66 Biggest Movers From Yesterday

By Lisa Levin

Today, 8:04 PM

Gainers

AMC

4 minute read

Uncategorized

52 Biggest Movers From Yesterday

By Lisa Levin

Today, 8:04 PM

Gainers Scopus BioPharma Inc. (NASDAQ: SCPS) shares climbed 72% to close at $10.25 on Monday after the company reported the FDA approval of IND application for CpG-STAT3siRNA, its distinctive immuno-oncology RNA therapy for the treatment of multiple cancers.

ALT